What long-acting injectable (LAI) antipsychotic medications are available in the U.S.?

See clinical tips available (linked below) on individual LAIs for more detailed information about what clinicians should know.


LAI Drug Name

FDA Indications

(Adult 18+ unless otherwise noted*)

Dosing Tips

(frequency of administration, oral overlap)

***First-Generation Antipsychotics***
Prolixin Decanoate (fluphenazine decanoate) 


  • 2-6 weeks
  • Overlap PO 4-8 weeks
Haldol Decanoate (haloperidol decanoate)


  • 4 weeks
  • Overlap PO 4 weeks
***Second-Generation Antipsychotics***
Abilify Maintena (aripiprazole monohydrate LAI)


Bipolar maintenance

  • 4 weeks
  • Overlap PO 2 weeks
Aristada (aripiprazole lauroxil LAI)


  • 4 or 6 or 8 weeks
  • Aristada Initio IM & PO 1 dose or
  • Overlap PO 3 weeks
Aristada Initio (aripiprazole lauroxil LAI)


  • Only for initiation of Aristada once
  • Given with Aristada first injection
Invega Sustenna (paliperidone palmitate LAI)


  • 4 weeks
  • Loading IM day 1 & day 8
Invega Trinza (paliperidone palmitate 12-week LAI)


  • 12 weeks
  • After 2 stable-dose Sustenna injections
Risperdal Consta (risperidone microspheres LAI)

Schizophrenia *age 13+

Bipolar I maintenance *age12+

  • 2 weeks
  • Overlap PO 3 weeks
Perseris (risperidone subcutaneous LAI)


  • 4 weeks
  • Subcutaneous (SC)
Zyprexa Relprevv (olanzapine LAI)


  • 2 or 4 weeks
  • Smoking status dosing considerations
  • Risk: Post-injection delirium sedation syndrome (PDSS) – registry required.
If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system: www.smiadviser.org/submit-consult. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!
  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

Saved Posts